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The ability of the immune system to recognize pathogens to which it was previously exposed 
depends on the formation of immunologic memory. Upon initial antigen recognition and activation, T 
cells expand and differentiate to effector T cells that mediate cytotoxic effects to clear the infection. 
Most effector T cells die, but subsets of memory T cells termed central and effector memory cells are 
formed during the primary response and patrol lymph nodes, blood and tissue sites for the life of the 
individual. These memory T cells have been proposed to function as stem cells by maintaining the 
ability to self-renew and differentiate into new effector T-cells in response to antigen re-encounter, 
but whether this function is provided by all memory subsets has been controversial. The ultimate 
proof of stemness requires the isolation, adoptive transfer, and fate mapping of individual cells to 
test for both self-renewal and multipotency. Using three generations of single-cell adoptive transfer 
and infection-driven expansion, a new study published in Immunity identifies the putative stem cell 
that provides immune memory as the central memory T cell.  
The experimental capability for this study was developed through a long-term collaboration, focused 
on clinical cell processing and purification, between researchers based in Munich, Germany and 
Seattle. This team included Dr. Stanley Riddell from the Clinical Research Division and senior fellow 
Hans Fischer and colleagues at the Institute for Advanced Study of the Technical University of 
Munich. The researchers assessed the stemness of isolated subsets of CD8 T cells. The separation 
of the subtypes of memory T cells extended from previous research in the Riddell laboratory that 
suggested the existence of memory T cells with stem-cell-like characteristics that protect 
chemotherapy patients from infection when the rest of their immune system is ablated (Turtle et al., 
2009). Memory T cells were isolated from the blood based on expression of specific cell surface 
markers, including CD62L. Central memory T cells (Tcm) express CD62L and are less prevalent in 
the blood while effector memory T cells (Tem) are CD62L-negative.  
In this study, single naïve T cells were first transferred into mice and then exposed to the bacteria 
Listeria monocytogenes to instigate formation of memory cells. At least two months after the initial 
infection subsided, the researchers isolated and transferred single Tcm cells that were derived from 
the progeny of the single naïve T cell and specific for Listeria into either immunocompetent or 
immunocompromised mice. The individual Tcm cells generated progeny of equal number and 
diversity upon secondary transfer after antigen re-exposure as the naïve T cell did upon first transfer. 
Furthermore, transfer of just ten secondary Tcm cells was sufficient to protect immunocompromised 
mice from a lethal challenge of Listeria monocytogenes.  
Only 20% of the mice developed T cell progeny after single naïve T cell or Tcm cell transfer, similar 
to the recovery rate of single hematopoietic stem cells, demonstrating the technological feat of these 
experiments. Importantly, the researchers found that not even 100 Tem could be propagated across 
serial adoptive transfers. This result supports a model of progressive differentiation in which the Tem 
and effector T cells that differentiate from Tcm lose self-renewal capabilities, while Tcm are 
maintained by self-renewal.  
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According to Dr. Riddell this paper "provides the first proof that central memory T cells are in 
essence 'stem cells' for an epitope specific immune response providing a mechanism for the 
longevity/durability of T cell memory." These studies also have implications for immunotherapy and 
current research by the Riddell Laboratory is harnessing the power of the immune system by 
redirecting specific subsets of T cells to recognize and kill tumor cells. T cells are harvested from 
patients and genetically engineered to target tumor cells in the laboratory, and then transferred back 
into patients. Specifically isolating and reprogramming CD62L-positive Tcm cells may improve the 
persistence and efficacy of adoptive T cell therapies. The study by Graef et al. further shows that 
smaller numbers of these cells could be used to reduce the cost of the treatments and expand the 
application of adoptive T cell therapy. Current clinical trials are underway to evaluate if use of these 
memory cells translates into increased tumor responses.  
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Image adapted from Gattinoni, 2014 
Serial adoptive transfer of single memory T cells positive for cell surface marker CD62L, followed by 
infection-driven expansions, demonstrates stemness of these memory T cell subsets. These central 
memory T cells are capable of protecting immunodeficient hosts from lethal bacterial challenge. 
 
